Postoperative conventional radiotherapy caused fewer head-and-neck symptoms and dominated preoperative accelerated radiotherapy in the five-year cost-utility analysis.
Combined FDG-PET and multiparametric MRI achieved only modest pCR prediction after neoadjuvant chemoradiotherapy, with a cross-validated AUC of 0.65.
BiHU-GAN generated synthetic contrast and non-contrast CT with high contour agreement and at least 95% gamma pass rates at 2%/2 mm.
Once-weekly prostate-and-pelvis SBRT reduced acute gastrointestinal toxicity versus conventional IMRT without significantly increasing genitourinary toxicity.
Higher postoperative CTV minimum BED10 was associated with lower local failure after separation surgery and spine SBRT.
A RapidPlan lung SBRT model generated clinically acceptable plans in 52% of validation cases on first optimization.
Single-field optimization improved proton LATTICE motion robustness
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
High-dose carbon ion re-irradiation achieved 83.1% 3-year survival with no grade 4 toxicity in recurrent pelvic sarcoma.
CT-guided online adaptive prostate SBRT was feasible, with adapted plans selected in 95% of fractions and dosimetric improvements in 85%.
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.
Twice-weekly 28 Gy in 5 fractions produced no grade 3 or higher toxicity and 98.8% excellent-to-good cosmesis at 1 year.
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
This systematic review found that optimal radiotherapy-immunotherapy sequencing depends on the immune mechanism being targeted.
VMAT-based lattice SFRT achieved cross-platform deliverability with gamma pass rates above 90% and preserved peak-to-valley dose ratios.